Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2023 Q2- Text added to 2023 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
New words:
AMRX, announced, binding, canceled, cardiac, carryforward, ceased, China, Chinese, clinical, conglomerate, converted, converting, costly, denosumab, equivalent, force, Fosun, guarantee, Hawaii, heard, implementation, implemented, imported, Intermediate, Mabxcience, manner, merger, Mobile, Nava, NDA, NewCo, OldPubCo, par, Pharma, PharmaSophia, preempted, procedural, procurement, Prolia, PubCo, QT, reclassification, Reorganization, reorganize, resubmit, routine, Samoa, shareholder, simplify, software, standby, structure, subcontract, supplier, surrendered, symbol, syndication, target, ticker, traditional, umbrella, XGEVA
Valuein 2023 Q2 filing- Value in 2023 Q3 filing
Original filings
Filing view